Navigation Links
Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
Date:1/9/2012

later stage trials in advanced AML. The Company's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs), as well as an OS improvement compared with historical data, in Phase I/II trials of adult patients with refractory or recurrent high grade glioma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.  

Forward-Looking Statements

This announcement contains forward-looking statements relating to Stemline's business, which are based on the Company's current expectations concerning future developments. These statements are subject to risks, uncertainties and other factors that may cause Stemline's actual performance to differ materially from the statements in this announcement. There can be no assurance that future developments affecting Stemline will be those the Company has anticipated.

Stemline Contact: 
Mark Jacobson 
Associate Director, Business Development  
Stemline Therapeutics, Inc. 
Tel: 212-584-5747 
Email: mjacobson@stemline.com


'/>"/>
SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Israele, February 27, 2015 ... nel suo sviluppo dell,innovativo sistema di monitoraggio dell,infarto ... primo trial sull,uomo-     ... nello sviluppo di nuovo sistema per il monitoraggio ... (CHF), ha annunciato oggi di aver concluso una ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... , LOS ANGELES, Aug. 7 A new ... any drug and sealed to the outer surface (episclera) of the ... of medicines for retinal and vitreous diseases, according to a new ... in The Vision Center at Children,s Hospital Los Angeles. Dr. Murphree ...
... , , CARLSBAD, Calif., Aug. ... its financial results for the quarter ended June 30, 2009. During ... a result reported $669,000 of pro forma net income for the quarter ... 2008. Isis also reported a pro forma net operating loss of $1.3 ...
Cached Medicine Technology:Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases 2Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases 3Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases 4Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 2Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 3Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 4Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 5Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 6Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 7Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 8Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 9Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 10Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 11Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 12Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 13Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 14Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 15Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 16Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 17Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 18Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 19Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 20Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 21Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009 22
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
(Date:2/28/2015)... The Heart Fit Clinic started doing External Counterpulsation ... The Heart Fit Clinic is also selling the machines ... The goal is to scale the business to help ... buy External Counterpulsation machines can be difficult process. ... process and achieve the desired results. , The ...
(Date:2/28/2015)... February 28, 2015 Mew and Company, ... that they now provide business consulting services in addition ... corporate tax planning and succession planning. Company finances are ... experienced professionals. On top of this, complex Canadian tax ... corporate accounting. As a result, Mew and Company works ...
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 Pioneer ... the 2015 Japan Architecture & Construction Materials Show, an ... join more than 1,000 suppliers and top manufacturers of ... Reclaimed wood products sourced and manufactured by ... have found popularity in Japan at restaurants, hotels, retailers, ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... developed for preventing and treating the flue have shown ... dose to be effective.// The compounds, known collectively as ... relenza, or zanamivir, which the U.S. Food and Drug ... B. ,Researchers reported at the International Conference on ...
... to be worrisome threats, common pest control agent called ... treatments in eradicating deadly bacterial spores from buildings. Tests ... 50 years to control insect pests in buildings, grain ... than current treatments such as chlorine dioxide for killing ...
... giant GlaxoSmithKline (GSK), under fire regarding its smoking cessation drug, ... - in the wake of unproven reports in the UK, ... , ,Touted to be the world’s most successful smoking cessation ... June 2001. The cause for concern, however, was a safety ...
... University Hospital, a common cholesterol fighting drug, a statin ... heart complications by up to 20 percent for about ... heart events -- such as dying of heart disease ... Dr. Patrick Serruys,// professor of interventional cardiology at Erasmus ...
... the Marquette University School of Dentistry suggest chronic periodontal ... diabetes.//The research ties the incidence of diabetes in patients ... the bloodstream that triggers a reaction from the immune ... release proteins called cytokines that can disrupt production of ...
... University of Texas in US have found that African American ... women.// Ovarian cancer causes more deaths than any other cancer ... ethnicity is an independent risk factor in prognosis. US researchers ... 600 African American women with ovarian cancer. They find that ...
Cached Medicine News:Health News:Cholesterol Drug Helps After Angioplasty 2Health News:Cholesterol Drug Helps After Angioplasty 3
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
... Colony Counter allows the user to quickly and ... allows for digital counting or manual counting. An ... lens increasing magnification to 3.0X. The adjustable focusing ... raised or lowered. The lens also rotates a ...
... Quebec Colony Counter allows the user to quickly ... models allows for digital counting or manual counting. ... standard lens increasing magnification to 3.0X. The adjustable ... be raised or lowered. The lens also rotates ...
The Accucount 1000 is designed to automatically count macroscopic objects in a field displaying totals on a highly visible digital readout....
Medicine Products: